Company intelligence / Profile preview

AccuraGen

Menlo Park, California, United Statesaccuragen.com ↗

Ownership: Private
Employees: ~16
Development stage: Commercial

Overview

AccuraGen has developed proprietary liquid biopsy technology using rolling-circle amplification to enable highly sensitive and specific detection of genetic mutations from blood samples. Their platform supports non-invasive cancer diagnostics and personalized treatment planning. The company has filed 27 patents related to DNA sequencing and molecular biology[1][2]. No clinical trial results are reported as they provide diagnostic services rather than therapeutics.

Therapeutic areas: Oncology
Modalities: Liquid biopsy (encompassing DNA and RNA sequencing for cancer diagnostics)
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on AccuraGen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AccuraGen.

Explore the full profile